title: Spinal fractures during fluoride therapy for osteoporosis: relationship to spinal bone density.
abstract: Recent studies report that fluoride therapy for osteoporosis increases spinal bone density without improving vertebral fracture rate, challenging the notion that restoration of bone mass improves bone fragility. To further evaluate this issue, the relationship between spinal bone density and vertebral fracture rate was examined in a large number of fluoride-treated, osteoporotic patients. A retrospective assessment was made of clinical data collected from our observations of 389 osteoporotics treated with fluoride 30 +/- 8 mg/day (mean +/- SD) (equivalent to 66 +/- 17 mg NaF/day) and calcium 1500 mg/day for 28 +/- 18 months. Fracture rate and bone density were assessed in the same region of the spine (i.e., T12 through L4) using quantitative computed tomography (QCT). Spinal bone density increased with time on fluoride, but the relationship was hyperbolic (r = 0.99, p less than 0.0001; asymptote = 167 mg/cc on double-reciprocal plot), suggesting a plateau in the response. The spinal fracture rate decreased as a function of time on therapy (r = -0.83, p less than 0.01), and was inversely related to spinal bone density during fluoride therapy (r = 0.70, p less than 0.001 on arithmetic plot; r = -0.79, p less than 0.001 on semi-log plot). The subgroup of patients who responded to treatment with a significant increase in spinal bone density had a 48% reduction in spinal fracture rate compared with non-responders (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Loma Linda University, California.
authors.forename: S M
authors.initials: SM
authors.lastname: Farley
authors.forename: J E
authors.initials: JE
authors.lastname: Wergedal
authors.forename: J R
authors.initials: JR
authors.lastname: Farley
authors.forename: G N
authors.initials: GN
authors.lastname: Javier
authors.forename: E E
authors.initials: EE
authors.lastname: Schulz
authors.forename: J R
authors.initials: JR
authors.lastname: Talbot
authors.forename: C R
authors.initials: CR
authors.lastname: Libanati
authors.forename: L
authors.initials: L
authors.lastname: Lindegren
authors.forename: M
authors.initials: M
authors.lastname: Bock
authors.forename: M M
authors.initials: MM
authors.lastname: Goette
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D015519:Bone Density; D005260:Female; D005459:Fluorides / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D012189:Retrospective Studies; D012307:Risk Factors; D016103:Spinal Fractures / Q000209:etiology*; D013131:Spine / Q000378:metabolism*
chemical_list: D005459:Fluorides